drugset / Trial / NCT00479037
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with primary osteoporosis.
Timeline
- Start
- 2007-04
- Primary completion
- 2009-02
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Parathyroid Hormone | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Strontium Ranelate | Small molecule | 2 g | Oral |